2. Academic Validation
  3. EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs

EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs

  • Cancers (Basel). 2018 Jan 12;10(1):19. doi: 10.3390/cancers10010019.
Joanna Macdonald 1,  Justin Henri 2,  Kislay Roy 3,  Emma Hays 4,  Michelle Bauer 5,  Rakesh Naduvile Veedu 6 7,  Normand Pouliot 8 9 10,  Sarah Shigdar 11 12
Affiliations

Affiliations

  • 1 School of Medicine, Deakin University, Geelong, VIC 3128, Australia. jmmacd@deakin.edu.au.
  • 2 School of Medicine, Deakin University, Geelong, VIC 3128, Australia. jhenri@deakin.edu.au.
  • 3 School of Medicine, Deakin University, Geelong, VIC 3128, Australia. kislay.roy@deakin.edu.au.
  • 4 School of Medicine, Deakin University, Geelong, VIC 3128, Australia. ehays@deakin.edu.au.
  • 5 School of Medicine, Deakin University, Geelong, VIC 3128, Australia. mbauer@deakin.edu.au.
  • 6 Centre for Comparative Genomics, Murdoch University, Perth, WA 6150, Australia. r.veedu@murdoch.edu.au.
  • 7 Perron Institute for Neurological and Translational Science, Perth, WA 6009, Australia. r.veedu@murdoch.edu.au.
  • 8 Department of Pathology and University of Melbourne, Melbourne, VIC 3010, Australia. normand.pouliot@onjcri.org.au.
  • 9 Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3000, Australia. normand.pouliot@onjcri.org.au.
  • 10 Matrix Microenvironment and Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Heidelberg, VIC 3084, Australia. normand.pouliot@onjcri.org.au.
  • 11 School of Medicine, Deakin University, Geelong, VIC 3128, Australia. sarah.shigdar@deakin.edu.au.
  • 12 Centre for Molecular and Medical Research, Deakin University, Geelong, VIC 3128, Australia. sarah.shigdar@deakin.edu.au.
PMID: 29329202 DOI: 10.3390/cancers10010019
Abstract

The epithelial cell adhesion molecule (EpCAM), or CD326, was one of the first Cancer associated biomarkers to be discovered. In the last forty years, this biomarker has been investigated for use in personalized Cancer therapy, with the first monoclonal antibody, edrecolomab, being trialled in humans more than thirty years ago. Since then, several Other monoclonal antibodies have been raised to EpCAM and tested in clinical trials. However, while monoclonal antibody therapy has been investigated against EpCAM for almost 40 years as primary or Adjuvant therapy, it has not shown as much promise as initially heralded. In this review, we look at the reasons why and consider alternative targeting options, such as Aptamers, to turn this almost ubiquitously expressed epithelial Cancer biomarker into a viable target for future personalized therapy.

Keywords

EpCAM; antibody; aptamer; cancer; immunotherapy; therapeutics.

Figures
Products